RT Journal Article
SR Electronic
T1 ACE2 polymorphisms as potential players in COVID-19 outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.27.20114843
DO 10.1101/2020.05.27.20114843
A1 Khayat, André Salim
A1 de Assumpção, Paulo Pimentel
A1 Khayat, Bruna Claudia Meireles
A1 Araújo, Taíssa Maíra Thomaz
A1 Batista-Gomes, Jéssica Almeida
A1 Imbiriba, Luciana Carvalho
A1 Ishak, Geraldo
A1 de Assumpção, Paula Baraúna
A1 Moreira, Fabiano Cordeiro
A1 Burbano, Rommel Rodriguez
A1 Ribeiro-dos-Santos, André
A1 Ribeiro-dos-Santos, Ândrea Kelly
A1 dos Santos, Ney Pereira Carneiro
A1 dos Santos, Sidney Emmanuel Batista
YR 2020
UL http://medrxiv.org/content/early/2020/05/29/2020.05.27.20114843.abstract
AB The clinical condition COVID-19, caused by SARS-CoV-2, was declared a pandemic by the WHO in March 2020. Currently, there are more than 5 million cases worldwide, and the pandemic has increased exponentially in many countries, with different incidences and death rates among regions/ethnicities and, intriguingly, between sexes. In addition to the many factors that can influence these discrepancies, we suggest a biological aspect, the genetic variation at the viral S protein receptor in human cells, ACE2 (angiotensin I-converting enzyme 2), which may contribute to the worse clinical outcome in males and in some regions worldwide. We performed exomics analysis in native and admixed South American populations, and we also conducted in silico genomics databank investigations in populations from other continents. Interestingly, at least ten polymorphisms in coding, noncoding and regulatory sites were found that can shed light on this issue and offer a plausible biological explanation for these epidemiological differences. In conclusion, ACE2 polymorphisms should influence epidemiological discrepancies observed among ancestry and, moreover, between sexes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementS.E.B.S received from The Brazilian National Council for Scientific and Technological Development (CNPq, www.cnpq.br) a financial support (number 431488/2016-9) to perform exome sequencing assays. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the National Committee for Ethics in Research (CONEP) and the Research Ethics Committee of the UFPA Tropical Medicine Center under CAAE number 20654313.6.0000.5172.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll 1000G files are available from the The International Genome Sample Resource database (number 20140730, reference GRCh37.p13; https://www.internationalgenome.org). All ABraOM files are available from the Brazilian genomic variants database (number 1.0.2, reference hg19; http://abraom.ib.usp.br/index.php). NAM and BAP data cannot be shared publicly because of these samples group is also enrolled in a broad project, in progressing. https://www.internationalgenome.org http://abraom.ib.usp.br/index.php